<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092026</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-UCB2009</org_study_id>
    <nct_id>NCT01092026</nct_id>
  </id_info>
  <brief_title>Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells</brief_title>
  <official_title>A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation&#xD;
      with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative&#xD;
      conditioning in patients with hematological malignancies.&#xD;
&#xD;
      This is a multicenter single arm, phase I-II pilot study. The primary objective of this study&#xD;
      is to determine the feasibility of UCB HSCT with co-infusion of third party mesenchymal stem&#xD;
      cells as assessed by the treatment-related mortality at d100 after transplant.&#xD;
&#xD;
      Patient inclusion criteria:&#xD;
&#xD;
      Age 15-60 yrs Patients for whom allogeneic stem cell transplantation is the preferred&#xD;
      treatment option, with the following hematological malignancies:acute myeloid leukemia, acute&#xD;
      lymphoblastic leukemia, high risk myelodysplastic syndrome, advanced lymphoproliferative&#xD;
      disorders, chronic myeloid leukemia (refractory or intolerant to second-line tyrosine kinase&#xD;
      inhibitors), multiple myeloma Informed consent given Patient exclusion criteria Previous&#xD;
      allogeneic transplant Progressive malignant disease Significant organ damage as a&#xD;
      contraindication to allotransplantation Significant psychiatric or neurological disorder&#xD;
      Uncontrolled viral, fungal or bacterial infection Pregnancy HIV positive Patients will&#xD;
      receive either myeloablative or reduced intensity conditioning. One or 2 cord blood&#xD;
      transplants will be transplanted, followed by infusion of a third-party mesenchymal stem cell&#xD;
      transplant Adverse event reporting BHS transplant committee will establish a protocol review&#xD;
      committee which will organize a central monitoring of the study. Within the context of&#xD;
      allogeneic HSCTx many severe events are likely to occur.&#xD;
&#xD;
      Statistics and stopping rules The trial will be stopped at any time that there is reasonable&#xD;
      evidence that the true rate of day +100 nonrelapse mortality exceeds 0.40. It is the&#xD;
      intention to include an initial 20 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL SYNOPSIS&#xD;
&#xD;
      Title of the study A pilot study to assess the feasibility of unrelated umbilical cord blood&#xD;
      transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or&#xD;
      nonmyeloablative conditioning in patients with hematological malignancies.&#xD;
&#xD;
      Design of the study This is a multicenter single arm, phase I-II pilot study.&#xD;
&#xD;
      Primary objective The primary objective of this study is to determine the feasibility of UCB&#xD;
      HSCT with co-infusion of third party mesenchymal stem cells as assessed by the&#xD;
      treatment-related mortality at d100 after transplant.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Chimerism at multiple time points&#xD;
&#xD;
        -  Hematopoietic recovery (neutrophil and platelet engraftment)&#xD;
&#xD;
        -  Immune recovery&#xD;
&#xD;
        -  Incidence of acute and chronic graft-versus-host disease (GVHD)&#xD;
&#xD;
        -  Infectious complications&#xD;
&#xD;
        -  Disease free survival&#xD;
&#xD;
        -  Relapse incidence&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
      Graft criteria&#xD;
&#xD;
        -  No peripheral blood or marrow donor available at the 9/10 compatibility level using high&#xD;
           resolution typing techniques&#xD;
&#xD;
        -  Adequate cord blood transplant available:&#xD;
&#xD;
           a)Single cord blood&#xD;
&#xD;
        -  Minimal 4/6 match (DR1-high, A-low, B-low)&#xD;
&#xD;
        -  Minimal 2 (6/6), 2.5 (5/6) or 3 (4/6) x 10exp7 nucleated cells per kg in the graft&#xD;
           b)Double cord blood&#xD;
&#xD;
        -  At least 4/6 common antigens shared by recipient and the 2 cord blood transplants&#xD;
&#xD;
        -  Minimal 3x 10exp7 nucleated cells per kg in the combined graft&#xD;
&#xD;
      Patient inclusion criteria&#xD;
&#xD;
        -  Age 15-60 yrs&#xD;
&#xD;
        -  Allogeneic stem cell transplantation is the preferred treatment option:&#xD;
&#xD;
           a)High risk acute myeloid leukemia (AML) in first complete remission (CR)&#xD;
&#xD;
        -  Preceding myelodysplastic syndrome&#xD;
&#xD;
        -  High risk karyotypes (e.g. monosomy 5 or 7, complex)&#xD;
&#xD;
        -  FLT3 alteration&#xD;
&#xD;
        -  &gt; 2 cycles to obtain CR&#xD;
&#xD;
        -  Erythroblastic or megakaryocytic leukemia b)High risk acute lymphoblastic leukemia (ALL)&#xD;
           in first CR&#xD;
&#xD;
        -  High risk karyotypes (e.g. t[9;22], t[4;11], t[1;19], complex)&#xD;
&#xD;
        -  MLL rearrangements c)Acute leukemia in second or third remission d)High risk&#xD;
           myelodysplastic syndrome: IPSS Intermediate-2 or high risk e)Advanced&#xD;
           lymphoproliferative disorders&#xD;
&#xD;
        -  Diffuse large B-cel non-Hodgkin lymphoma (NHL) or mantle cell NHL or B-prolymphocytic&#xD;
           leukemia&#xD;
&#xD;
             -  Sensitive relapse after autologous HSCTx&#xD;
&#xD;
        -  T-prolymphocytic leukemia&#xD;
&#xD;
        -  Chronic lymphocytic leukemia&#xD;
&#xD;
             -  Refractory to fludarabine&#xD;
&#xD;
             -  Adverse karyotypes (del p17) f)Chronic myeloid leukemia&#xD;
&#xD;
        -  Refractory or intolerant to second-line tyrosine kinase inhibitors g)Multiple myeloma&#xD;
&#xD;
        -  Advanced disease (selected cases)&#xD;
&#xD;
        -  Informed consent given&#xD;
&#xD;
      Patient exclusion criteria&#xD;
&#xD;
        -  Previous allogeneic transplant&#xD;
&#xD;
        -  Progressive malignant disease&#xD;
&#xD;
        -  Significant organ damage as a contraindication to allotransplantation&#xD;
&#xD;
             -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
             -  AST/ALT &gt; 3x normal value and/or serum bilirubin &gt;3 mg/dL&#xD;
&#xD;
             -  Cardiac failure (LVEF &lt; 50%)&#xD;
&#xD;
             -  Clinical relevant pulmonary disease: DLCO &lt; 50% normal&#xD;
&#xD;
        -  Significant psychiatric or neurological disorder&#xD;
&#xD;
        -  Uncontrolled viral, fungal or bacterial infection&#xD;
&#xD;
        -  Pregnancy&#xD;
&#xD;
        -  HIV positive&#xD;
&#xD;
      Study procedure Patients will receive either myeloablative or reduced intensity conditioning.&#xD;
      One or 2 cord blood transplants will be transplanted, followed by infusion of a third-party&#xD;
      mesenchymal stem cell transplant&#xD;
&#xD;
      Adverse event reporting BHS transplant committee will establish a protocol review committee&#xD;
      which will organize a central monitoring of the study. Within the context of allogeneic HSCTx&#xD;
      many severe events are likely to occur.&#xD;
&#xD;
      Statistics and stopping rules The trial will be stopped at any time that there is reasonable&#xD;
      evidence that the true rate of day +100 nonrelapse mortality exceeds 0.40. It is the&#xD;
      intention to include an initial 20 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment-related mortality</measure>
    <time_frame>day 100 after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic recovery</measure>
    <time_frame>One year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>cord blood transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cord blood transplantation</intervention_name>
    <description>One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen</description>
    <arm_group_label>cord blood transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Allogeneic stem cell transplantation is the preferred treatment option:&#xD;
&#xD;
          -  High risk acute myeloid leukemia (AML) in first complete remission (CR)&#xD;
&#xD;
          -  Preceding myelodysplastic syndrome&#xD;
&#xD;
          -  High risk karyotypes (e.g. monosomy 5 or 7, complex)&#xD;
&#xD;
          -  FLT3 alteration&#xD;
&#xD;
          -  &gt; 2 cycles to obtain CR&#xD;
&#xD;
          -  Erythroblastic or megakaryocytic leukemia&#xD;
&#xD;
          -  High risk acute lymphoblastic leukemia (ALL) in first CR&#xD;
&#xD;
          -  High risk karyotypes (e.g. t[9;22], t[4;11], t[1;19], complex)&#xD;
&#xD;
          -  MLL rearrangements&#xD;
&#xD;
          -  Acute leukemia in second or third remission&#xD;
&#xD;
          -  High risk myelodysplastic syndrome: IPSS Intermediate-2 or high risk&#xD;
&#xD;
          -  Advanced lymphoproliferative disorders&#xD;
&#xD;
          -  Diffuse large B-cel non-Hodgkin lymphoma (NHL) or mantle cell NHL or&#xD;
&#xD;
          -  B-prolymphocytic leukemia&#xD;
&#xD;
          -  Sensitive relapse after autologous HSCTx&#xD;
&#xD;
          -  T-prolymphocytic leukemia&#xD;
&#xD;
          -  Chronic lymphocytic leukemia&#xD;
&#xD;
          -  Refractory to fludarabine&#xD;
&#xD;
          -  Adverse karyotypes (del p17)&#xD;
&#xD;
          -  Chronic myeloid leukemia&#xD;
&#xD;
          -  Refractory or intolerant to second-line tyrosine kinase inhibitors&#xD;
&#xD;
          -  Multiple myeloma&#xD;
&#xD;
          -  Advanced disease (selected cases)&#xD;
&#xD;
          -  Informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous allogeneic transplant&#xD;
&#xD;
          -  Progressive malignant disease&#xD;
&#xD;
          -  Significant organ damage as a contraindication to allotransplantation&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  AST/ALT &gt; 3x normal value and/or serum bilirubin &gt; 3 mg/dL&#xD;
&#xD;
          -  Cardiac failure (LVEF &lt; 50%)&#xD;
&#xD;
          -  Clinical relevant pulmonary disease: DLCO &lt; 50% normal&#xD;
&#xD;
          -  Significant psychiatric or neurological disorder&#xD;
&#xD;
          -  Uncontrolled viral, fungal or bacterial infection&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rik Schots, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rik Schots, MD, PhD</last_name>
    <phone>+3224763105</phone>
    <email>Rik.Schots@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorien Deneve</last_name>
    <phone>+3224776040</phone>
    <email>Dorien.Deneve@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Schots, MD, PhD</last_name>
      <phone>+3224776211</phone>
      <email>Rik.Schots@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Dorien Deneve</last_name>
      <phone>+3224776040</phone>
      <email>Dorien.Deneve@uzbrussel.be.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

